Tanabe pens deal to sell plants to Towa in post-buyout pivot
Tanabe pens deal to sell plants to Towa in post-buyout pivot (BioSpace.)
Mitsubishi Tanabe Pharma
TSE: 4508 ~$15B MCAP
Mitsubishi Tanabe Pharma is a Japanese pharmaceutical company with a portfolio spanning immunology, central nervous system disorders, diabetes, and vaccines. It is the originator of Radicava (edaravone) for ALS and has been divesting non-core plants as part of a post-buyout strategic pivot.